RedChemExpress

Product Data Sheet

Guselkumab

Cat. No.:	HY-P9931
CAS No.:	1350289-85-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Description	Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with K _d values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research ^[1] .		
IC ₅₀ & Target	IL-23	IL-23 0.06 nM (IC ₅₀)	
In Vitro	Guselkumab inhibits IL-23 (0.5 splenocyteswith IC ₅₀ ranging (NKL cells. Guselkumab has no Guselkumab combines with IB STAT3 phosphorylation with a . Guselkumab blocks hIL-23-in nM. In another experiment, Gu MCE has not independently co	i or 1 ng/mL)-mediated production of Th17 cytokines IL17A, IL-17F, and IL-22 in mouse 0.016-0.080 nM. And, it inhibits IL-23 (10 or 100 ng/mL)-mediated production of IL-10 in human effect on IL-12 (0.1 ng/mL)-mediated production of interferon γ (IFNγ) in NK92MI cells. ^[1] . 31112 blocks IL-23-induced STAT3 phosphorylation, and Guselkumab blocks IL-23-induced an IC ₅₀ value of 102.1100±2.0053 nM ^[2] . induced mIL-17 production in a dose-dependent manner, exhibiting an IC ₅₀ of 4.9743 ±1.2847 uselkumab also blocks IL-17F production in cynomolgus monkeys with an IC ₅₀ of 16.7950 nM ^[2] .	

REFERENCES

[1]. International non-proprietary name: guselkumab Procedure No. EMEA/H/C/004271/0000par-public-assessment-report_en.pdf

[2]. Li Li, et al. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int Immunopharmacol

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fa

Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA